User: Guest  Login
Document type:
journal article 
Author(s):
von Minckwitz, G; Rezai, M; Tesch, H; Huober, J; Gerber, B; Zahm, D M; Hilfrich, J; Costa, S D; Dubsky, P; Blohmer, J U; Denkert, C; Hanusch, C; Jackisch, C; Kümmel, S; Fasching, P A; Schneeweiss, A; Paepke, S; Untch, M; Burchardi, N; Mehta, K; Loibl, S; German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators 
Title:
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). 
Abstract:
Patients with invasive residual disease after neoadjuvant chemotherapy (NACT) are considered to have chemo-resistant breast cancer. Bisphosphonates are an established treatment for bone metastases and are of potential benefit as adjuvant treatment in early breast cancer.Patients who had invasive tumour residuals (ypT1-4 and/or ypN+) after a minimum of four cycles of anthracycline-taxane-containing NACT were eligible for the NeoAdjuvant Trial Add-oN study. Patients were randomised within 3 years...    »
 
Journal title abbreviation:
Eur J Cancer 
Year:
2016 
Journal volume:
64 
Pages contribution:
12-21 
Language:
eng 
Print-ISSN:
0959-8049 
TUM Institution:
Frauenklinik und Poliklinik